Discover

ALGS
Aligos Therapeutics, Inc.
6.89
2 x 6.50
1 x 6.85
bid
ask
+
0.12
1.77%
44 @ 04:00 PM
6.75 -0.14 (2.04%)
Ytd-26.07%
1y-9.22%
6.58
day range
6.97
4.08
52 week range
13.30
Open6.75Prev Close6.77Low6.58High6.97Mkt Cap42.64M
Vol65.56KAvg Vol185.42KEPS-7.30P/E-0.94Forward P/E-3.30
Beta2.12Short Ratio0.50Inst. Own48.86%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg5.47200-d Avg7.211yr Est103.33
Income Statement
Total Revenue27.78M
Revenues (USD)27.78M
Gross Profit27.78M
Operating Expenses29.67M
Research and Development Expense24.05M
Selling, General and Administrative Expense5.62M
Operating Income-1.89M
Interest Expense-221.00K
Income Tax Expense2.81M
Net Income-1.50M
Net Income Common Stock-1.50M
Net Income Common Stock (USD)-1.50M
Consolidated Income-1.50M
Earnings per Basic Share-0.14
Earnings per Basic Share (USD)-0.14
Earnings per Diluted Share-0.14
Earning Before Interest & Taxes (EBIT)1.09M
Earning Before Interest & Taxes (USD)1.09M
Weighted Average Shares10.43M
Weighted Average Shares Diluted10.43M
Balance Sheet
Cash and Equivalents30.42M
Cash and Equivalents (USD)30.42M
Trade and Non-Trade Receivables27.78M
Current Assets62.13M
Property, Plant & Equipment Net3.44M
Total Assets66.33M
Debt Current3.22M
Total Debt3.50M
Current Liabilities28.34M
Debt Non-Current288.00K
Total Liabilities34.44M
Accumulated Retained Earnings (Deficit)-666.74M
Accumulated Other Comprehensive Income437.00K
Shareholders Equity31.88M
Shareholders Equity (USD)31.88M
Assets Non-Current4.20M
Total Debt (USD)3.50M
Liabilities Non-Current6.10M
Trade and Non-Trade Payables6.43M
Cash Flow
Depreciation, Amortization & Accretion728.00K
Net Cash Flow from Financing220.00K
Net Cash Flow / Change in Cash & Cash Equivalents269.00K
Capital Expenditure-1000
Issuance (Purchase) of Equity Shares236.00K
Issuance (Repayment) of Debt Securities -16.00K
Net Cash Flow from Investing25.00M
Net Cash Flow - Investment Acquisitions and Disposals25.00M
Net Cash Flow from Operations-24.95M
Share Based Compensation1.36M